Figure 3.

Simulated number of SARS-CoV-2 cases when face masks are used for different durations after the final vaccination coverage is achieved

(A) 70% vaccine efficacy with SARS-CoV-2 R₀=5, and vaccination coverage achieved by Jan 1, 2022. (B) 70% vaccine efficacy with SARS-CoV-2 R₀=8, and vaccination coverage achieved by Jan 1, 2022. (C) 70% vaccine efficacy with SARS-CoV-2 R₀=5, and vaccination coverage achieved by March 1, 2022. (D) 70% vaccine efficacy with SARS-CoV-2 R₀=8, and vaccination coverage achieved by March 1, 2022. (E) 50% vaccine efficacy with SARS-CoV-2 R₀=5, and vaccination coverage achieved by Jan 1, 2022. (F) 50% vaccine efficacy with SARS-CoV-2 R₀=5, and vaccination coverage achieved by March 1, 2022. Maintaining face mask use for longer provided more benefits with lower vaccine efficacies and with increases in R₀. Note the differences in scales across the panels, which was done to more readily see when outcomes levelled off with increases in the time face masks were used.